Recognizing the Experts Driving Innovation in Leptomeningeal Metastases Diagnostics

On Employee Appreciation Day, we want to recognize and thank the incredible CNSide® team members whose dedication, expertise, and hard work continue to support the commercialization and advancement of the CNSide Diagnostic Assay Platform.

Behind every diagnostic innovation is a team of passionate professionals committed to improving patient care and advancing solutions for some of the most challenging cancers. At CNSide Diagnostics, our employees play a critical role in helping expand access to advanced diagnostic testing for patients with leptomeningeal metastases (LM).

Today, we celebrate the individuals across our laboratory, operations, clinical, commercial, and support teams who make this work possible every day.

Advancing CNSide® Diagnostics Through Collaboration and Innovation

Commercializing an advanced oncology diagnostic platform requires collaboration across multiple disciplines. From laboratory operations and scientific development to clinician education and patient support, the CNSide team works together toward a shared mission: helping address the unmet diagnostic needs associated with leptomeningeal metastases.

CNSide® is designed to detect and characterize tumor cells in cerebrospinal fluid (CSF), supporting enhanced diagnostic insights in patients with suspected LM. As awareness and adoption continue to grow, our employees remain at the center of every milestone and achievement.

Their commitment helps drive:

• Expansion of CNSide availability for testing including CSF 
• Ongoing laboratory excellence and quality standards
• Clinical education and physician engagement
• Innovation in neuro-oncology diagnostics
• Improved support for healthcare providers and patients

Every contribution matters, and every team member helps move the mission forward.

Supporting Physicians and Patients in Neuro-Oncology

Leptomeningeal metastases remain one of the most difficult-to-diagnose complications of advanced cancer. Physicians often face significant challenges in obtaining timely and accurate diagnostic information, making innovation in this area critically important.

The CNSide team is proud to support healthcare providers with advanced diagnostic solutions designed specifically for this complex disease state.

As commercialization efforts continue, our employees remain focused on delivering operational excellence while helping expand awareness of CNSide among oncologists, neuro-oncologists, pathologists, and healthcare systems nationwide.

Interested in Learning More About CNSide®?

Healthcare providers and organizations interested in learning more about the CNSide Diagnostic Assay Platform for leptomeningeal metastases can join our interest list to receive updates and additional information.

Join the CNSide Interest List here: CNSide Interest List

About CNSide® Diagnostics

CNSide® is a proprietary diagnostic platform designed to detect and characterize tumor cells in cerebrospinal fluid (CSF) from patients with leptomeningeal metastases. The platform combines advanced technologies to support enhanced diagnostic insights and help address unmet needs in neuro-oncology.nsights and help address unmet needs in neuro-oncology.